-
Ao Z, Patel A, Tran K, He X, Fowke K, Coombs K, Kobasa D, Kobinger G, Yao X, 2008: Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules[J]. Antiviral Res, 79, 12-18. doi: 10.1016/j.antiviral.2008.02.001
-
Braciale T J, Morrison L A, Sweetser M T, Sambrook J, Gething M J, Braciale V L, 1987: Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes[J]. Immunol. Rev., 98, 95-114. doi: 10.1111/imr.1987.98.issue-1
-
Bresson J L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon M C, 2006: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial[J]. Lancet, 367, 1657-1664. doi: 10.1016/S0140-6736(06)68656-X
-
Chen J, Lee K H, Steinhauer D A, Stevens D J, Skehel J J, Wiley D C, 1998: Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation[J]. Cell, 95, 409-417. doi: 10.1016/S0092-8674(00)81771-7
-
Claas E C, Osterhaus A D, van Beek R, De Jong J C, Rimmelzwaan G F, Senne D A, Krauss S, Shortridge K F, Webster R G, 1998: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus[J]. Lancet, 351, 472-477. doi: 10.1016/S0140-6736(97)11212-0
-
Ehrlich H J, Muller M, Oh H M, Tambyah P A, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova B G, Pollabauer E M, Kistner O, Barrett P N, 2008: A clinical trial of a whole-virus H5N1 vaccine derived from cell culture[J]. N Engl J Med, 358, 2573-2584. doi: 10.1056/NEJMoa073121
-
Garcia J M, Lagarde N, Ma E S, de Jong M D, Peiris J S, 2010: Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay[J]. J. Clin. Virol., 47, 29-33. doi: 10.1016/j.jcv.2009.10.009
-
Giroglou T, Cinatl J, Rabenau H, Drosten C, Schwalbe H, Doerr H W, von Laer D, 2004: Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein[J]. J. Virol., 78, 9007-9015. doi: 10.1128/JVI.78.17.9007-9015.2004
-
Haynes J R, Dokken L, Wiley J A, Cawthon A G, Bigger J, Harmsen A G, Richardson C, 2009: Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge[J]. Vaccine, 27, 530-541. doi: 10.1016/j.vaccine.2008.11.011
-
Herfst S, Schrauwen E J, Linster M, Chutinimitkul S, de Wit E, Munster V J, Sorrell E M, Bestebroer T M, Burke D F, Smith D J, Rimmelzwaan G F, Osterhaus A D, Fouchier R A, 2012: Airborne transmission of influenza A/H5N1 virus between ferrets[J]. Science, 336, 1534-1541. doi: 10.1126/science.1213362
-
Ho J W, Hershkovitz O, Peiris M, Zilka A, Bar-Ilan A, Nal B, Chu K, Kudelko M, Kam Y W, Achdout H, Mandelboim M, Altmeyer R, Mandelboim O, Bruzzone R, Porgador A, 2008: H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44[J]. J. Virol., 82, 2028-2032. doi: 10.1128/JVI.02065-07
-
Horimoto T, Kawaoka Y, 1994: Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus[J]. J. Virol., 68, 3120-3128.
-
Horimoto T, Nakayama K, Smeekens S P, Kawaoka Y, 1994: Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses[J]. J. Virol., 68, 6074-6078.
-
Howard M K, Kistner O, Barrett P N, 2008: Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines[J]. Biological Chemistry, 389, 569-577.
-
Imai M, Watanabe T, Hatta M, Das S C, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher E A, Neumann G, Kawaoka Y, 2012: Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets[J]. Nature, 486, 420-428.
-
Kistner O, Howard M K, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe B A, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner F G, Barrett P N, 2007: Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses[J]. Vaccine, 25, 6028-6036. doi: 10.1016/j.vaccine.2007.05.013
-
Kong W P, Hood C, Yang Z Y, Wei C J, Xu L, Garcia-Sastre A, Tumpey T M, Nabel G J, 2006: Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination[J]. Proc. Natl. Acad. Sci. U.S.A., 103, 15987-15991. doi: 10.1073/pnas.0607564103
-
Li S, Liu C, Klimov A, Subbarao K, Perdue M L, Mo D, Ji Y, Woods L, Hietala S, Bryant M, 1999: Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses[J]. J. Infect. Dis., 179, 1132-1138. doi: 10.1086/jid.1999.179.issue-5
-
Lin A H, Cannon P M, 2002: Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype)[J]. Virus Res., 83, 43-56. doi: 10.1016/S0168-1702(01)00407-5
-
Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Wang X, Wood J, Feng Z, Wang Y, Yin W, 2006: Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial[J]. Lancet, 368, 991-997. doi: 10.1016/S0140-6736(06)69294-5
-
Lu B, Tao L, Wang T, Zheng Z, Li B, Chen Z, Huang Y, Hu Q, Wang H, 2009: Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice[J]. Clin. Vaccine Immunol., 16, 73-77. doi: 10.1128/CVI.00261-08
-
Lu X, Tumpey T M, Morken T, Zaki S R, Cox N J, Katz J M, 1999: A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans[J]. J Virol, 73, 5903-5911.
-
Nefkens I, Garcia J M, Ling C S, Lagarde N, Nicholls J, Tang D J, Peiris M, Buchy P, Altmeyer R, 2007: Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis[J]. J. Clin. Virol., 39, 27-33. doi: 10.1016/j.jcv.2007.02.005
-
Okumura Y, Takahashi E, Yano M, Ohuchi M, Daidoji T, Nakaya T, Bottcher E, Garten W, Klenk H D, Kido H, 2010: Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication[J]. J. Virol., 84, 5089-5096. doi: 10.1128/JVI.02605-09
-
Schrauwen E J, Herfst S, Leijten L M, van Run P, Bestebroer T M, Linster M, Bodewes R, Kreijtz J H, Rimmelzwaan G F, Osterhaus A D, Fouchier R A, Kuiken T, van Riel D, 2012: The multibasic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets[J]. J Virol, 86, 3975-3984. doi: 10.1128/JVI.06828-11
-
Senne D A, Panigrahy B, Kawaoka Y, Pearson J E, Suss J, Lipkind M, Kida H, Webster R G, 1996: Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential[J]. Avian Dis, 40, 425-437. doi: 10.2307/1592241
-
Skehel J J, Wiley D C, 2000: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin[J]. Annu Rev Biochem, 69, 531-569. doi: 10.1146/annurev.biochem.69.1.531
-
Song J M, Hossain J, Yoo D G, Lipatov A S, Davis C T, Quan F S, Chen L M, Hogan R J, Donis R O, Compans R W, Kang S M, 2010: Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles[J]. Virology, 405, 165-175. doi: 10.1016/j.virol.2010.05.034
-
Stech J, Garn H, Wegmann M, Wagner R, Klenk H D, 2005: A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin[J]. Nat Med, 11, 683-689. doi: 10.1038/nm1256
-
Steinhauer D A, 1999: Role of hemagglutinin cleavage for the pathogenicity of influenza virus[J]. Virology, 258, 1-20. doi: 10.1006/viro.1999.9716
-
Stieneke-Grober A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk H D, Garten W, 1992: Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease[J]. EMBO J., 11, 2407-2414.
-
Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y, 2003: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics[J]. Virology, 305, 192-200. doi: 10.1006/viro.2002.1742
-
Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N, 1998: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness[J]. Science, 279, 393-396. doi: 10.1126/science.279.5349.393
-
Suguitan A L, Marino M P, Desai P D, Chen L M, Matsuoka Y, Donis R O, Jin H, Swayne D E, Kemble G, Subbarao K, 2009: The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus[J]. Virology, 395, 280-288. doi: 10.1016/j.virol.2009.09.017
-
Suguitan A L Jr., Matsuoka Y, Lau Y F, Santos C P, Vogel L, Cheng L I, Orandle M, Subbarao K, 2012: The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals[J]. J Virol, 86, 2706-2714. doi: 10.1128/JVI.05546-11
-
Szecsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk H D, Klatzmann D, Volchkov V, Cosset F L, 2006: Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses[J]. Virol. J., 3, 70-. doi: 10.1186/1743-422X-3-70
-
Tambyah P A, Wilder-Smith A, Pavlova B G, Barrett P N, Oh H M, Hui D S, Yuen K Y, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich H J, 2012: Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine[J]. Vaccine, 30, 329-335. doi: 10.1016/j.vaccine.2011.10.088
-
Tao L, Chen J, Zheng Z, Meng J, Zhang Z, Chen Y, Luo H, Li H, Chen Z, Hu Q, Wang H, 2012: H5N1 influenza virus-like particles produced by transient expression in mammalian cells induce humoral and cellular immune responses in mice[J]. Can J Microbiol, 58, 391-401. doi: 10.1139/w2012-006
-
Temperton N J, Hoschler K, Major D, Nicolson C, Manvell R, Hien V M, Ha do Q, de Jong M, Zambon M, Takeuchi Y, Weiss R A, 2007: A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies[J]. Influenza Other Respi Viruses, 1, 105-112. doi: 10.1111/irv.2007.1.issue-3
-
Tsai C G, Caillet C, Hu H X, Zhou F, Ding H, Zhang G L, Zhou B P, Wang S X, Lu S, Buchy P, Deubel V, Vogel F R, Zhou P, 2009: Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase[J]. Vaccine, 27, 6777-6790. doi: 10.1016/j.vaccine.2009.08.056
-
Wang S Y, Su C Y, Lin M, Huang S Y, Huang W I, Wang C C, Wu Y T, Cheng T J, Yu H M, Ren C T, Wu C Y, Wong C H, Cheng Y S, 2009: HA-pseudotyped retroviral vectors for influenza antagonist screening[J]. J Biomol Screen, 14, 294-302. doi: 10.1177/1087057108330786
-
Wang S Y, Su C Y, Lin M G, Huang S Y, Huang W I, Wang C C, Wu Y T, Cheng T J R, Yu H M, Ren C T, Wu C Y, Wong C H, Cheng Y S E, 2009: HA-Pseudotyped Retroviral Vectors for Influenza Antagonist Screening[J]. J. Biomol. Screen., 14, 294-302. doi: 10.1177/1087057108330786
-
Wang W, Xie H, Ye Z, Vassell R, Weiss C D, 2010: Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays[J]. J. Virol. Methods, 165, 305-310. doi: 10.1016/j.jviromet.2010.02.009
-
Wang W, Butler E N, Veguilla V, Vassell R, Thomas J T, Moos M, Ye Z P, Hancock K, Weiss C D, 2008: Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies[J]. J. Virol. Methods, 153, 111-119. doi: 10.1016/j.jviromet.2008.07.015
-
Webby R J, Perez D R, Coleman J S, Guan Y, Knight J H, Govorkova E A, McClain-Moss L R, Peiris J S, Rehg J E, Tuomanen E I, Webster R G, 2004: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines[J]. Lancet, 363, 1099-1103. doi: 10.1016/S0140-6736(04)15892-3
-
WHO. 2013. Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2013.
-
Wu C Y, Yeh Y C, Yang Y C, Chou C, Liu M T, Wu H S, Chan J T, Hsiao P W, 2010: Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus[J]. PLoS One, 5, -.
-
Wu Q, Fang L, Wu X, Li B, Luo R, Yu Z, Jin M, Chen H, Xiao S, 2009: A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens[J]. Mol. Immunol., 46, 2210-2217. doi: 10.1016/j.molimm.2009.04.017
-
Yin J, Liu S, Zhu Y, 2013: An overview of the highly pathogenic H5N1 influenza virus[J]. Virol Sin, 28, 3-15. doi: 10.1007/s12250-013-3294-9
-
Zhang S, Xiao L, Zhou H, Yu Z, Chen H, Guo A, Jin M, 2008: Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus[J]. J. Virol. Methods, 154, 99-103. doi: 10.1016/j.jviromet.2008.08.016
-
Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z, 2009: A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice[J]. BMC Infect. Dis., 9, 17-. doi: 10.1186/1471-2334-9-17